Expression of Activator Protein-1 (AP-1) Family Members in Breast Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2013 Oct 1

PMID 24073962

Citations 55

Authors

Amirhossein Kharman-Biz

Hui Gao

Reza Ghiasvand

Chunyan Zhao

Kazem Zendehdel

Karin Dahlman-Wright

Affiliations

Soon will be listed here.

Abstract

Background: The activator protein-1 (AP-1) transcription factor is believed to be important in tumorigenesis and altered AP-1 activity was associated with cell transformation. We aimed to assess the potential role of AP-1 family members as novel biomarkers in breast cancer.

Methods: We studied the expression of AP-1 members at the mRNA level in 72 primary breast tumors and 37 adjacent non-tumor tissues and evaluated its correlation with clinicopathological parameters including estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status. Expression levels of Ubiquitin C (UBC) were used for normalization. Protein expression of AP-1 members was assessed using Western blot analysis in a subset of tumors. We used student's t-test, one-way ANOVA, logistic regression and Pearson's correlation coefficient for statistical analyses.

Results: We found significant differences in the expression of AP-1 family members between tumor and adjacent non-tumor tissues for all AP-1 family members except Fos B. Fra-1, Fra-2, Jun-B and Jun-D mRNA levels were significantly higher in tumors compared to adjacent non-tumor tissues (p < 0.001), whilst c-Fos and c-Jun mRNA levels were significantly lower in tumors compared with adjacent non-tumor tissues (p < 0.001). In addition, Jun-B overexpression had outstanding discrimination ability to differentiate tumor tissues from adjacent non-tumor tissues as determined by ROC curve analysis. Moreover, Fra-1 was significantly overexpressed in the tumors biochemically classified as ERα negative (p = 0.012) and PR negative (p = 0.037). Interestingly, Fra-1 expression was significantly higher in triple-negative tumors compared with luminal carcinomas (p = 0.01).

Conclusions: Expression levels of Fra-1 and Jun-B might be possible biomarkers for prognosis of breast cancer.

Citing Articles

The RRP9-JUN axis promotes breast cancer progression via the AKT signalling pathway.

Huan J, Liu X, Wang N, Mu Y, Li L, Du Y Biol Direct. 2024; 19(1):131.

PMID: 39702367 PMC: 11660783. DOI: 10.1186/s13062-024-00578-8.

TNFAIP2 promotes HIF1α transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis.

Ren W, Liang H, Sun J, Cheng Z, Liu W, Wu Y Cell Death Dis. 2024; 15(11):821.

PMID: 39532855 PMC: 11557851. DOI: 10.1038/s41419-024-07223-2.

Interaction of NF-κB and FOSL1 drives glioma stemness.

Ramar V, Guo S, Hudson B, Khedri A, Guo A, Li J Cell Mol Life Sci. 2024; 81(1):255.

PMID: 38856747 PMC: 11335291. DOI: 10.1007/s00018-024-05293-1.

Expression of PVRL4, a molecular target for cancer treatment, is transcriptionally regulated by FOS.

Nanamiya T, Takane K, Yamaguchi K, Okawara Y, Arakawa M, Saku A Oncol Rep. 2023; 51(1).

PMID: 38063270 PMC: 10739986. DOI: 10.3892/or.2023.8676.

JunB: a paradigm for Jun family in immune response and cancer.

Ren F, Cai X, Yao Y, Fang G Front Cell Infect Microbiol. 2023; 13:1222265.

PMID: 37731821 PMC: 10507257. DOI: 10.3389/fcimb.2023.1222265.

References

Logullo A, Stiepcich M, Osorio C, Nonogaki S, Pasini F, Rocha R . Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma. Histopathology. 2011; 58(4):617-25. PMC: 3085077. DOI: 10.1111/j.1365-2559.2011.03785.x. View

Milde-Langosch K, Roder H, Andritzky B, Aslan B, Hemminger G, Brinkmann A . The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat. 2004; 86(2):139-52. DOI: 10.1023/B:BREA.0000032982.49024.71. View

Mousavi S, Zheng T, Dastgiri S, Miller A . Age distribution of breast cancer in the middle East, implications for screening. Breast J. 2009; 15(6):677-9. DOI: 10.1111/j.1524-4741.2009.00843.x. View

Angel P, Karin M . The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991; 1072(2-3):129-57. DOI: 10.1016/0304-419x(91)90011-9. View

Pike M, Spicer D, Dahmoush L, Press M . Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993; 15(1):17-35. DOI: 10.1093/oxfordjournals.epirev.a036102. View

El Saghir N, Seoud M, Khalil M, Charafeddine M, Salem Z, Geara F . Effects of young age at presentation on survival in breast cancer. BMC Cancer. 2006; 6:194. PMC: 1555600. DOI: 10.1186/1471-2407-6-194. View

Montazeri A, Ebrahimi M, Mehrdad N, Ansari M, Sajadian A . Delayed presentation in breast cancer: a study in Iranian women. BMC Womens Health. 2003; 3(1):4. PMC: 166160. DOI: 10.1186/1472-6874-3-4. View

Belguise K, Milord S, Galtier F, Moquet-Torcy G, Piechaczyk M, Chalbos D . The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells. Oncogene. 2012; 31(47):4889-97. PMC: 3624663. DOI: 10.1038/onc.2011.659. View

Schroder C, Schumacher U, Muller V, Wirtz R, Streichert T, Richter U . The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells. Eur J Cancer. 2010; 46(9):1650-60. DOI: 10.1016/j.ejca.2010.02.008. View

10.

Belguise K, Kersual N, Galtier F, Chalbos D . FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene. 2004; 24(8):1434-44. DOI: 10.1038/sj.onc.1208312. View

11.

LaValley M . Logistic regression. Circulation. 2008; 117(18):2395-9. DOI: 10.1161/CIRCULATIONAHA.106.682658. View

12.

Ali S, Coombes R . Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2003; 2(2):101-12. DOI: 10.1038/nrc721. View

13.

Chiappetta G, Ferraro A, Botti G, Monaco M, Pasquinelli R, Vuttariello E . FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer. 2007; 7:17. PMC: 1796888. DOI: 10.1186/1471-2407-7-17. View

14.

Smith L, Birrer M, Stampfer M, Brown P . Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Cancer Res. 1997; 57(14):3046-54. View

15.

OBrien K, Cole S, Tse C, Perou C, Carey L, Foulkes W . Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res. 2010; 16(24):6100-10. PMC: 3029098. DOI: 10.1158/1078-0432.CCR-10-1533. View

16.

Weigel M, Dowsett M . Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010; 17(4):R245-62. DOI: 10.1677/ERC-10-0136. View

17.

Kushner P, Agard D, Greene G, Scanlan T, Shiau A, Uht R . Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2001; 74(5):311-7. DOI: 10.1016/s0960-0760(00)00108-4. View

18.

Bamberger A, Methner C, Lisboa B, Stadtler C, Schulte H, Loning T . Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer. 1999; 84(5):533-8. DOI: 10.1002/(sici)1097-0215(19991022)84:5<533::aid-ijc16>3.0.co;2-j. View

19.

Huang W, Newman B, Millikan R, Schell M, Hulka B, Moorman P . Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol. 2001; 151(7):703-14. DOI: 10.1093/oxfordjournals.aje.a010265. View

20.

Potter J, Cerhan J, Sellers T, McGovern P, Drinkard C, Kushi L . Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there?. Cancer Epidemiol Biomarkers Prev. 1995; 4(4):319-26. View